Frank-Piskorska A, Wasek Z, Malinowski R
Wiad Lek. 1989 Mar 1;42(5):278-83.
In 113 patients and 33 controls the bronchodilating effect of three most frequently used calcium channel blockers nifedipine, verapamil and diltiazem was studied. The group comprised 76 men and 41 women aged 20 to 60 years, with bronchospastic conditions of various aetiology. The Jaeger Bodytest apparatus was used. The indices of bronchial patency determined in the study were: FEV1, MEF50, and Rt before and 30 and 120 minutes after one dose of nifedipine 20 mg, verapamil 80 mg and diltiazem 120 mg in various subgroups of patients. The criteria of bronchospasm reversibility were those accepted by SEPCR. It was shown that oral administration of one mean dose of calcium channel blocker causes improvement of the indices of bronchial patency in about one-third of cases contrary to the results in controls. The bronchodilating effect was greatest after nifedipine. The obtained results justify the trials of treatment with calcium channel antagonists in cases with reversible bronchospasm of various aetiology.
对113例患者和33例对照者研究了三种最常用的钙通道阻滞剂硝苯地平、维拉帕米和地尔硫䓬的支气管舒张作用。该组包括76名男性和41名女性，年龄在20至60岁之间，患有各种病因的支气管痉挛性疾病。使用了耶格人体测试仪。在研究中测定的支气管通畅指标为：在不同亚组患者中，分别给予20 mg硝苯地平、80 mg维拉帕米和120 mg地尔硫䓬一剂之前、之后30分钟和120分钟的第一秒用力呼气量（FEV1）、最大呼气中期流速（MEF50）和气道阻力（Rt）。支气管痉挛可逆性的标准为西班牙胸科和心血管外科学会（SEPCR）所认可的标准。结果显示，口服一剂平均剂量的钙通道阻滞剂后，约三分之一的病例支气管通畅指标得到改善，这与对照组的结果相反。硝苯地平后的支气管舒张作用最大。所得结果证明了在各种病因的可逆性支气管痉挛病例中试用钙通道拮抗剂治疗的合理性。
